CN1250571C - 用于闪烁显像术的特异结合分子、含有这些特异分子的偶连物以及其用途 - Google Patents

用于闪烁显像术的特异结合分子、含有这些特异分子的偶连物以及其用途 Download PDF

Info

Publication number
CN1250571C
CN1250571C CNB998060526A CN99806052A CN1250571C CN 1250571 C CN1250571 C CN 1250571C CN B998060526 A CNB998060526 A CN B998060526A CN 99806052 A CN99806052 A CN 99806052A CN 1250571 C CN1250571 C CN 1250571C
Authority
CN
China
Prior art keywords
antibody
angiogenesis
domain
antibody according
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998060526A
Other languages
English (en)
Chinese (zh)
Other versions
CN1303393A (zh
Inventor
D·尼里
L·塔里
F·维提
M·伯彻勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ETH Zurich
Original Assignee
ETH Zurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/300,425 external-priority patent/US20030045681A1/en
Application filed by ETH Zurich filed Critical ETH Zurich
Publication of CN1303393A publication Critical patent/CN1303393A/zh
Application granted granted Critical
Publication of CN1250571C publication Critical patent/CN1250571C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB998060526A 1998-05-11 1999-05-11 用于闪烁显像术的特异结合分子、含有这些特异分子的偶连物以及其用途 Expired - Lifetime CN1250571C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7533898A 1998-05-11 1998-05-11
US09/075,338 1998-05-11
US09/300,425 1999-04-28
US09/300,425 US20030045681A1 (en) 1998-05-11 1999-04-28 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Publications (2)

Publication Number Publication Date
CN1303393A CN1303393A (zh) 2001-07-11
CN1250571C true CN1250571C (zh) 2006-04-12

Family

ID=26756726

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998060526A Expired - Lifetime CN1250571C (zh) 1998-05-11 1999-05-11 用于闪烁显像术的特异结合分子、含有这些特异分子的偶连物以及其用途

Country Status (24)

Country Link
US (1) US20070189963A1 (cg-RX-API-DMAC10.html)
EP (1) EP1084145B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002514405A (cg-RX-API-DMAC10.html)
CN (1) CN1250571C (cg-RX-API-DMAC10.html)
AT (1) ATE301676T1 (cg-RX-API-DMAC10.html)
AU (1) AU759207B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI9910394B8 (cg-RX-API-DMAC10.html)
CA (1) CA2333833C (cg-RX-API-DMAC10.html)
CZ (1) CZ300495B6 (cg-RX-API-DMAC10.html)
DE (1) DE69926630T2 (cg-RX-API-DMAC10.html)
DK (1) DK1084145T3 (cg-RX-API-DMAC10.html)
EA (1) EA005685B1 (cg-RX-API-DMAC10.html)
EE (1) EE05435B1 (cg-RX-API-DMAC10.html)
ES (1) ES2247802T3 (cg-RX-API-DMAC10.html)
HU (1) HU225675B1 (cg-RX-API-DMAC10.html)
IL (1) IL139452A0 (cg-RX-API-DMAC10.html)
IS (1) IS2522B (cg-RX-API-DMAC10.html)
NO (1) NO327732B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ508600A (cg-RX-API-DMAC10.html)
PL (1) PL199353B1 (cg-RX-API-DMAC10.html)
SK (1) SK286822B6 (cg-RX-API-DMAC10.html)
TR (1) TR200003317T2 (cg-RX-API-DMAC10.html)
TW (1) TWI259837B (cg-RX-API-DMAC10.html)
WO (1) WO1999058570A2 (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
NZ511219A (en) * 1999-01-05 2003-05-30 Univ Southern Australia Novel agents and methods for treatment and diagnosis of ocular disorders
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US20020197700A1 (en) * 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
DE10045803A1 (de) * 2000-09-07 2002-04-11 Schering Ag Rezeptor der EDb Fibronektin-Domäne
US20030100010A1 (en) * 2001-11-23 2003-05-29 George Jackowski Fibrinogen biopolymer Marker predictive of type II diabetes
WO2003047633A2 (en) * 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
PL369371A1 (en) * 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
DK1461360T3 (da) * 2002-01-03 2010-11-15 Bayer Schering Pharma Ag Konjugater omfattende et antistofspecifik for ED-8-domæner af fibronectin og deres anvendelse til påvisning og behandling af tumorer
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1957531B1 (en) * 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
DE502005009389D1 (de) * 2005-11-09 2010-05-20 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
JP2009244154A (ja) 2008-03-31 2009-10-22 Nationa Hospital Organization 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
US20110306065A1 (en) * 2008-11-12 2011-12-15 The Trustees Of The University Of Pennsylvania Use of an antibody and a rare-earth based crystal
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
DK2721152T3 (da) 2011-06-15 2019-07-01 Navigo Proteins Gmbh Dimere bindingsproteiner baseret på modificerede ubiquitiner
US9549981B2 (en) 2011-07-19 2017-01-24 Philogen S.P.A. Sequential antibody therapy
RU2481839C2 (ru) * 2011-08-16 2013-05-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
EP3029065B1 (en) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
DK3322721T3 (da) 2015-07-16 2022-03-14 Navigo Proteins Gmbh Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
EP3378947B1 (en) * 2015-11-16 2024-01-24 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11230576B2 (en) 2016-08-11 2022-01-25 Navigo Proteins Gmbh Alkaline stable immunoglobulin-binding proteins
IL310865A (en) 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3689903A4 (en) * 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. BINDING OF PROTEIN TO FIBRONECTIN B DOMAIN
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
KR20210104106A (ko) 2018-12-18 2021-08-24 나피고 프로타인스 게엠베하 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질
JP2024524891A (ja) 2021-06-23 2024-07-09 サイチューン ファーマ インターロイキン-15に基づく免疫サイトカイン
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン15多様体
US20250073239A1 (en) 2022-01-04 2025-03-06 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2024028258A1 (en) 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
AU2023332212A1 (en) 2022-09-01 2025-04-10 Philogen S.P.A. Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer
CA3266566A1 (en) 2022-09-06 2024-03-14 Philochem Ag MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
EP4780495A1 (en) 2023-09-19 2026-07-29 Philochem AG Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods

Also Published As

Publication number Publication date
US20070189963A1 (en) 2007-08-16
ATE301676T1 (de) 2005-08-15
HUP0102992A2 (hu) 2001-11-28
BRPI9910394B8 (pt) 2021-07-06
NO20005694L (no) 2001-01-10
TR200003317T2 (tr) 2001-07-23
WO1999058570A2 (en) 1999-11-18
IS5708A (is) 2000-11-10
DE69926630T2 (de) 2006-05-24
NO327732B1 (no) 2009-09-14
HUP0102992A3 (en) 2003-09-29
EE05435B1 (et) 2011-06-15
EE200000802A (et) 2002-06-17
DK1084145T3 (da) 2005-12-19
HU225675B1 (en) 2007-06-28
CN1303393A (zh) 2001-07-11
EA200001169A1 (ru) 2001-04-23
IL139452A0 (en) 2001-11-25
PL345845A1 (en) 2002-01-14
EA005685B1 (ru) 2005-04-28
EP1084145A2 (en) 2001-03-21
TWI259837B (en) 2006-08-11
CA2333833A1 (en) 1999-11-18
NO20005694D0 (no) 2000-11-10
PL199353B1 (pl) 2008-09-30
DE69926630D1 (de) 2005-09-15
ES2247802T3 (es) 2006-03-01
SK16792000A3 (sk) 2001-05-10
JP2002514405A (ja) 2002-05-21
AU759207B2 (en) 2003-04-10
NZ508600A (en) 2003-03-28
SK286822B6 (sk) 2009-06-05
EP1084145B1 (en) 2005-08-10
WO1999058570A3 (en) 2000-03-16
CZ20004216A3 (en) 2001-05-16
CA2333833C (en) 2011-01-25
CZ300495B6 (cs) 2009-06-03
BRPI9910394B1 (pt) 2013-07-02
BRPI9910394A (pt) 2001-01-09
AU4039899A (en) 1999-11-29
IS2522B (is) 2009-07-15

Similar Documents

Publication Publication Date Title
CN1303393A (zh) 用于闪烁显像术的特异结合分子、含有这些特异分子的偶连物以及用于血管生成治疗的方法
JP7190901B2 (ja) 前立腺特異的膜抗原(psma)と結合する分子
CN1427891A (zh) 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法
CN110099697B (zh) 用于消融造血干细胞的抗体药物缀合物
CN1596313A (zh) 人源化的胶原抗体及相关方法
JP2022506310A (ja) 抗CD79b抗体、その薬物複合体及びその応用
KR100744370B1 (ko) 신티그래피용 특이 결합 분자,이를 함유하는 접합체 및맥관형성의 치료방법
CN1753911A (zh) 调节血管生成的α5β1整合素的嵌合的和人源化的抗体
CN1922199A (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
CN1308676A (zh) 抗cd23抗体、抗cd23抗体衍生物及其治疗性应用
CN101035564A (zh) 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物
CN1795009A (zh) 抗-cd33抗体和使用其治疗急性髓性白血病的方法
JP2022519273A (ja) 抗cd228抗体及び抗体薬物コンジュゲート
CN1639195A (zh) 应用抗体分子对肿瘤血管进行选择性定向
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1849144A (zh) 使用放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管
US20210228731A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
WO2022152144A1 (zh) 结合cd73的蛋白及其应用
CN1878792A (zh) Nogo-a结合分子及其药物用途
JP5102612B2 (ja) B細胞疾患の標的
CN1961004A (zh) 作为潜在抗肿瘤治疗剂的单克隆抗体sc104及其特异性结合至唾液酸丁糖基碳水化合物的衍生物
US20220251206A1 (en) Anti-ctla4 antibody prodruggable (probody) at a cdr position
HK1053670A (en) Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
CN103374071B (zh) 一种抗derlin‑1人源化抗体的制备
HK1075254A (en) Tumor specific monoclonal antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20060412

CX01 Expiry of patent term